TB Alliance

EU leaders seek new tools against drug-resistant TB

EU leaders urge funding for new treatment and prevention tools against drug-resistant TB.

Read More →

TB Alliance sublicenses promising TB drug from the Medicines Patent Pool

Agreement announced on World Tuberculosis Day revitalizes efforts to develop sutezolid as effective response to infectious disease killer.

Read More →

World TB Day event: Innovating to End TB

USAID and TB Alliance will host an event, Innovating to End TB on 14 March 2017, 12:00 PM – 6:30 PM EDT in Washington, D.C., United States.

Read More →

Clinical trial of BPaMZ regimen will replace Phase 3 STAND trial

NEW YORK (21 December, 2016)—TB Alliance announced, based on positive results from the Phase 2b NC-005 trial, that it will now plan a Phase 3 study to test the BPaMZ (bedaquiline + pretomanid + moxifloxacin + pyrazinamide) regimen. In light of these results, where the BPaMZ regimen appears to be much more promising compared to the PaMZ (pretomanid + moxifloxacin + pyrazinamide) regimen, the STAND trial testing the PaMZ regimen will not be reopened to new patients. 

Read More →

German government announces support for new TB treatments

The government of Germany has announced its support for the development of new treatments to combat tuberculosis (TB). Germany’s Federal Ministry of Education and Research (BMBF) has committed EUR 10 million over five years to TB Alliance, facilitated by the KfW development bank. This grant is part of a slate of support intended to spur product development to fight neglected diseases.

Read More →

TB Alliance partners with PepsiCo to advance the fight for improved medicines for children

October 27, 2016 (LIVERPOOL, ENGLAND) – TB Alliance, a non-profit organization dedicated to developing better and faster cures for tuberculosis (TB), today announced a unique collaboration with food and beverage company PepsiCo designed to improve the treatment for children with TB.  Many of today’s TB treatments are very bitter or unpleasant in taste, which when compounded with the long duration of treatment for TB, can lead to low tolerance and poor compliance – especially among children. 

Read More →

Kenya becomes first country to introduce new child-friendly TB medicines

New products expected to improve treatment and child survival from TB; Starting October 1 all children in Kenya initiated on TB treatment will be given the improved formulation.

Read More →

TB Alliance Stakeholders Association: Call for community representative

The Global Alliance for TB Drug Development (TB Alliance) is seeking applications for the community representative to its Stakeholders Association.

Read More →

Penn State, TB Alliance, and GSK partner to discover new treatments for TB

UNIVERSITY PARK, Pa., June 27, 2016 -- A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).

Read More →

TB Alliance and Takeda announce advancement of joint program investigating promising compounds for novel TB therapies

NEW YORK AND OSAKA (June 21, 2016) — TB Alliance and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced that they have entered into an agreement that further explores hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis (TB). The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases.

Read More →

Page 1 of 6 · Total posts: 10

1 2 Last→